{
    "id": "wrong_mix_random_starring_00027_1",
    "rank": 92,
    "data": {
        "url": "https://cancer.ufl.edu/2021/06/03/uf-at-the-asco-annual-meeting-2021/",
        "read_more_link": "",
        "language": "en",
        "title": "UF at the ASCO Annual Meeting 2021",
        "top_image": "https://cancer.ufl.edu/files/2021/06/download-1.png",
        "meta_img": "https://cancer.ufl.edu/files/2021/06/download-1.png",
        "images": [
            "https://cdn.webservices.ufhealth.org/wp-content/themes/ufhealth-apollo/dist/assets/images/ufhealth-monogram.svg?id=e254fc09",
            "https://cancer.ufl.edu/wordpress/files/2021/06/am21-blog.png",
            "https://cancer.ufl.edu/wordpress/files/2023/05/CancerCenter_h_CMYK_COLOR_Badge-1-220x88.png",
            "https://cdn.webservices.ufhealth.org/wp-content/themes/ufhealth-apollo/dist/assets/images/ufhealth-monogram.svg?id=e254fc09",
            "https://cdn.webservices.ufhealth.org/wp-content/themes/ufhealth-apollo/dist/assets/images/gift.svg?id=6f799c83",
            "https://cdn.webservices.ufhealth.org/wp-content/themes/ufhealth-apollo/dist/assets/images/ufhealth-full.svg?id=48323e9f",
            "https://cdn.webservices.ufhealth.org/wp-content/themes/ufhealth-apollo/dist/assets/images/uf-full.svg?id=450d80d1"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2021-06-03T00:00:00",
        "summary": "",
        "meta_description": "Physicians and researchers from the University of Florida are participating in the virtual American Society of Clinical Oncology (ASCO) meeting held on June 4-8, 2021. The ASCO Annual Meeting is one of the largest gatherings of medical professionals in the world. It brings together more than 25,000 oncology professionals from a broad range of specialties…",
        "meta_lang": "en",
        "meta_favicon": "https://cdn.webservices.ufhealth.org/wp-content/themes/ufhealth-apollo/preprocess/assets/images/favicon-ufhealth.ico",
        "meta_site_name": "",
        "canonical_link": "https://cancer.ufl.edu/2021/06/03/uf-at-the-asco-annual-meeting-2021/",
        "text": "Physicians and researchers from the University of Florida are participating in the virtual American Society of Clinical Oncology (ASCO) meeting held on June 4-8, 2021.\n\nThe ASCO Annual Meeting is one of the largest gatherings of medical professionals in the world. It brings together more than 25,000 oncology professionals from a broad range of specialties for five days of cutting-edge scientific presentations. View the full conference program is available here.\n\nThe theme for this year’s meeting asks attendees to identify ways to ensure that all patients can access and benefit from the latest cancer advances and high-quality cancer care. “Equity: Every Patient. Every Day. Everywhere” highlights the importance for oncology professionals to use this moment of cancer progress to make certain that health equity in cancer care becomes a reality for all patients. The names of UF collaborators are bolded below.\n\nAbstracts\n\nPatterns of telehealth utilization during the COVID-19 pandemic and preferences for post-pandemic telehealth use: A national survey of oncology clinicians.1580 – Session: Care Delivery and Regulatory Policy\n\nChristopher Manz, Nancy N. Baxter, Nefertiti C. duPont, Merry Jennifer Markham, Caitlin Drumheller, Lela Durakovic, Angela Kennedy, ASCO Telehealth Disparities Taskforce; University of Pennsylvania, Philadelphia, PA; St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; Roswell Park Cancer Institute, Buffalo, NY; University of Florida, Gainesville, FL; American Society of Clinical Oncology, Alexandria, VA\n\nPeople with cancer are likely to accept the COVID-19 vaccine, but politics tracks with attitudes: An inspire and COSMO survey\n\n1531 – Session: Care Delivery and Regulatory Policy\n\nDon S. Dizon, Kathleen D. Hoffman, Danielle Gentile, Richard Tsai, John Novack, Deanna J. Attai, Merry Jennifer Markham, Heather Marie Hylton, Lidia Schapira, David L. Graham, Michael A. Thompson, Collaboration for Outcomes using Social Media in Oncology (COSMO); Lifespan Cancer Institute and Brown University, Providence, RI; Inspire, Arlington, VA; Levine Cancer Institute, Charlotte, NC; David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Florida, Gainesville, FL; Association of Physician Assistants in Oncology, Altamonte Springs, FL; Stanford University and Stanford Cancer Institute, Stanford, CA; Levine Cancer Institute, Carolinas HealthCare System, Cornelius, NC; Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI\n\nLandscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology (IO) biomarkers.\n\n3127 – Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology\n\nMohamed E. Salem, Sherif El-Refai, Wei Sha, Axel Grothey, Alberto Puccini, Thomas J. George, Jimmy J. Hwang, Laura W. Musselwhite, David King, Kunal C. Kadakia, Derek Raghavan, Eric Van Cutsem, Josep Tabernero, Jeanne Tie; Levine Cancer Institute, Atrium Health, Charlotte, NC; Tempus Labs, Chicago, IL; Levine Cancer Inistitute, Charlotte, NC; West Cancer Center, OneOncology, Germantown, TN; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; University of Florida/UF Health Cancer Center, Gainesville, FL; Levine Cancer Institute, Charlotte, NC; Duke Cancer Institute, Duke University Medical Center, Durham, NC; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium; Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain; Peter MacCallum Cancer Centre, Melbourne, Australia\n\nPhase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).\n\nTPS3622 – Session: Gastrointestinal Cancer—Colorectal and Anal\n\nVan K. Morris, Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal, Patrick M Boland, Dustin A. Deming, Aaron James Scott, Howard John Lim, Norman Wolmark, Thomas J. George; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Pittsburgh Department of Biostatistics, and NRG Oncology Statistics and Data Management Center, Pittsburgh, PA; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; NSABP/NRG Oncology, Pittsburgh, PA; NSABP/NRG Oncology, and The UPMC Hillman Cancer Center, Pittsburgh, PA; NRG Oncology, and Baylor College of Medicine, Houston, TX; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin Carbone Cancer Center, and ECOG-ACRIN, Madison, WI; Banner-University of Arizona Cancer Center, Division of Hematology and Oncology, Tucson, AZ; British Columbia Cancer Vancouver, and CCTG Co-Chair, Vancouver, BC, Canada; University of Florida/UF Health Cancer Center, Gainesville, FL\n\nCirculating tumor DNA-based genomic profiling of small bowel adenocarcinoma.\n\n3523 – Session: Gastrointestinal Cancer—Colorectal and Anal\n\nPat Gulhati, Karan Pandya, Hiba I. Dada, Christopher R. Cogle, Jason S. Starr, Sujith R. Kalmadi, Fadi S. Braiteh, Leylah Drusbosky; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Guardant Health, Inc., Redwood City, CA; Brio Ventures, Gainesville, FL; University of Florida Health Cancer Center, Jacksonville, FL; Ironwood Cancer/Rsrch Ctr, Chandler, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV\n\nClinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.3597 – Session: Gastrointestinal Cancer—Colorectal and Anal\n\nZhaohui Jin, Jesse G. Dixon, Hiral Parekh, Frank A. Sinicrope, Greg Yothers, Daniel G. Haller, Hans Schmoll, Aimery De Gramont, Rachel Kerr, Julien Taieb, Eric Van Cutsem, Chris Twelves, Leonard B. Saltz, Naohiro Tomita, Takayuki Yoshino, Thierry Andre, Amit Mahipal, Richard M. Goldberg, Thomas J. George, Qian Shi; Division of Medical Oncology, Mayo Clinic, Rochester, MN; Department of Health Science Research, Mayo Clinic, Rochester, MN; Cancer Specialist of North Florida, Jacksonville, FL; Mayo Clinic, Rochester, MN; University of Pittsburgh Department of Biostatistics, and NRG Oncology Statistics and Data Management Center, Pittsburgh, PA; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Martin Luther University, Halle, Germany; Franco-British Institute, Levallois-Perret, France; University of Oxford, Oxford, United Kingdom; Hôpital Européen Georges Pompidou, Paris, France; University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium; St. James’s Hospital and The University of Leeds, Leeds, United Kingdom; Department of Colorectal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Sorbonne Université and Hôpital-Saint Antoine, Paris, France; West Virginia University Cancer Institute, Morgantown, WV; University of Florida/UF Health Cancer Center, Gainesville, FL\n\nColorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.\n\nTPS3618 – Session: Gastrointestinal Cancer—Colorectal and Anal\n\nMichael J. Overman, Greg Yothers, Samuel A. Jacobs, Hanna Kelly Sanoff, Deirdre Jill Cohen, Katherine A Guthrie, Norah Lynn Henry, Patricia A. Ganz, Scott Kopetz, Peter C. Lucas, Charles David Blanke, Norman Wolmark, Howard S. Hochster, Thomas J. George, Caio Max Sao Pedro Rocha Lima; University of Texas MD Anderson Cancer Center, and SWOG, Houston, TX; University of Pittsburgh Department of Biostatistics, and NRG Oncology Statistics and Data Management Center, Pittsburgh, PA; NSABP/NRG Oncology, Pittsburgh, PA; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill and Alliance, Chapel Hill, NC; Icahn School of Medicine at Mount Sinai and ECOG-ACRIN, New York, NY; Fred Hutchinson Cancer Research Center, and SWOG Statistics and Data Management Center, Seattle, WA; Department of Internal Medicine, University of Michigan Medical School and SWOG, Ann Arbor, MI; NRG Oncology, and UCLA Jonsson Comprehensive Cancer Center at UCLA, UCLA Fielding School of Public Health, Los Angeles, CA; NRG Oncology and Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Ctr, Houston, TX; NRG Oncology, and University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA; SWOG Cancer Research Network Group Chair’s Office, Oregon Health and Science University Knight Cancer Institute, Portland, OR; NSABP/NRG Oncology, and The UPMC Hillman Cancer Center, Pittsburgh, PA; NRG Oncology, and Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; NRG Oncology, and The University of Florida Health Cancer Center, Gainesville, FL; NRG Oncology, and Wake Forest University Baptist Medical Center, Winston-Salem, NC\n\nExamination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.3516 – Session: Gastrointestinal Cancer—Colorectal and Anal\n\nKatherine L. Pogue-Geile, Marion Joy, Ying Wang, Nan Song, Rim S. Kim, Greg Yothers, Carmen Joseph Allegra, Ashok Srinivasan, Melanie Finnigan, Samuel A. Jacobs, Soonmyung Paik, Jennifer Marie Marie Suga, Judith O. Hopkins, Nicholas J. DiBella, Naoyuki G. Saito, Peter C. Lucas, Norman Wolmark; NSABP/NRG Oncology, Pittsburgh, PA; University of Pittsburgh Department of Biostatistics, and NRG Oncology Statistics and Data Management Center, Pittsburgh, PA; NRG Oncology, and The University of Florida, Gainesville, FL; NRG Oncology/NSABP, and the Yonsei University College of Medicine, Seoul, PA; NSABP/NRG Oncology, and Kaiser Permanente NCI Community Oncology Research Program, Vallejo, CA; NSABP/NRG Oncology, and Novant Helath Forsyth Medical Center/Southeast Clinical Oncology Research Consortium, Winston Salem, NC; NSABP/NRG Oncology, Rocky Mt Cancer Ctrs, and Western States Cancer Research NCORP, Aurora, CO; NSABP/NRG Oncology, and the Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; NSABP/NRG Oncology, and The UPMC Hillman Cancer Center, Pittsburgh, PA\n\nA phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038).\n\nTPS4170 – Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary\n\nSherise C. Rogers, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Z. Hugh Fan, Carmen Joseph Allegra, Jose Trevino, Ahmad El-Far, Anita Ahmed Turk, Karen Bullock Russell, David L. DeRemer, Thomas J. George; University of Florida/UF Health Cancer Center, Gainesville, FL; University of Florida, Gainesville, FL; NSABP/NRG Oncology, and The University of Florida Health, Gainesville, FL; University of Florida Health Cancer Center, Gainesville, FL; University of Florida Health Cancer Center–Orlando Health, Orlando, FL; Department of Medicine, Hematology/Oncology, Indiana University Simon Cancer Center, Indianapolis, IN; Tallahassee Memorial Hospital, Tallahassee, FL; NRG Oncology, and The University of Florida Health Cancer Center, Gainesville, FL\n\nSBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma.4127 – Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary\n\nNimit Singhal, Darren Sigal, Niall C. Tebbutt, Aram F Hezel, Adnan Nagrial, Sumit Lumba, Thomas J. George, Sheri Lynn Smith, Suzanne Gagnon, Michael Walker, Michael T. Cullen; Adelaide Cancer Centre, Kurralta Park, SA, Australia; Department of Hematology and Oncology, Scripps Clinic and Scripps MD Anderson Cancer Center, San Diego, CA; Olivia Newton-John Cancer, Wellness and Research Centre, Austin Health, Heidelberg, VIC, Australia; University of Rochester Medical Center, Rochester, NY; Blacktown Hospital Cancer and Haematology Centre, Blacktown, NSW, Australia; John Flynn Private Hospital, Tugun, QLD, Australia; University of Florida/UF Health Cancer Center, Gainesville, FL; Courante Oncology, Excelsior, MN; Panbela Therapeutics, Inc., Minneapolis, MN\n\nUpdated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).\n\n4078 – Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary\n\nAnthony B. El-Khoueiry, Richard D. Kim, William Proctor Harris, Max W. Sung, Dirk Waldschmidt, Roniel Cabrera, Vittorio Luigi Garosi, Hong Zebger-Gong, Barbara J. Brennan, Ying A. Wang, Udo Mueller, Tatiane Cristine Ishida, Peter R. Galle; University of Southern California, Los Angeles, CA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Washington/Seattle Cancer Care Alliance (SCCA), Seattle, WA; Tisch Cancer Institute at Mount Sinai, New York, NY; University Hospital Cologne, Cologne, Germany; University of Florida, Gainesville, FL; Bayer S.p.A., Milan, Italy; Bayer AG, Berlin, Germany; Bayer HealthCare Pharmaceuticals, Whippany, NJ; Bayer HealthCare Pharmaceuticals, Cambridge, MA; ClinStat GmbH, Cologne, Germany; University Medical Center Mainz, Mainz, Germany\n\nInitial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).\n\n6565 – Session: Health Services Research and Quality Improvement\n\nLarissa A. Korde, Ana F. Best, Sacha Gnjatic, Andrea M. Denicoff, Grace E. Mishkin, Melissa Bowman, Lyndsay Harris, Ann M. Geiger, Worta J. McCaskill-Stevens, Stephen J. Chanock, Patricia Spears, Lawrence Rubinstein, Nicholas M. Mark, Jeremy Lyle Warner, Carmen Joseph Allegra, Adam J. Esbenshade, Michael V. Knopp, James H. Doroshow, Brian I. Rini, NCCAPS Study Team; Clinical Investigations Branch, National Cancer Institute, Bethesda, MD; National Cancer Institute, Rockville, MD; The Tisch Cancer Institute at Mount Sinai Health System, New York, NY; The Emmes Company, LLC, Rockville, MD; Cancer Diagnosis Program, National Cancer Institute, Rockville, MD; National Cancer Institute at the National Institutes of Health, Rockville, MD; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD; Cancer Information and Support Network, Raleigh, NC; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD; Swedish Medical Center, Seatle, WA; Vanderbilt-Ingram Cancer Center, Nashville, TN; NSABP/NRG Oncology, and The University of Florida Health, Gainesville, FL; Department of Pediatrics, Vanderbilt University School of Medicine and the Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, TN; Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH; National Cancer Institute, Bethesda, MD\n\nHealth-related quality of life (HRQoL) in patients (pts) with myelodysplastic syndromes (MDS) in the Connect Myeloid Disease Registry.7040 – Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant\n\nDennis A. Revicki, David L. Grinblatt, Rami S. Komrokji, Guillermo Garcia-Manero, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, E. Dawn Flick, Adeola Y. Makinde, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Irene S. DeGutis, Christopher R. Cogle; Outcomes Research Consulting, Sarasota, FL; NorthShore University Health System, Evanston, IL; Moffitt Cancer Center, Tampa, FL; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN; Fred Hutchinson Cancer Research Center, Seattle, WA; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL; Bristol Myers Squibb, Princeton, NJ; University of Florida, Gainesville, FL\n\nMelflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.\n\n8048 – Session: Hematologic Malignancies—Plasma Cell Dyscrasia\n\nPaula Rodríguez-Otero, Maria-Victoria Mateos, Albert Oriol, Alessandra Larocca, Joan Blade, Michele Cavo, Xavier Leleu, Omar Nadeem, John W. Hiemenz, Hani Hassoun, Cyrille Touzeau, Adrian Alegre, Agne Paner, Christopher Maisel, Amitabha Mazumder, Anastasios Raptis, Marcus Thuresson, Johan Harmenberg, Olof Harlin, Paul G. Richardson; Clinica Universidad De Navarra, Pamplona, Spain; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain; Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; CHU de Poitiers, Poitiers, France; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Division of Hematology-Oncology, Department of Medicine, University of Florida, Gainesville, FL; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, NY; University Hospital, Nantes, France CRCINA, INSERM, Centre National de la Recherche Scientifique, University of Angers, University of Nantes, Nantes, France; Hospital Universitario La Princesa and Hospital Universitario Quironsalud, Madrid, Spain; Rush University Medical Center, Chicago, IL; Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, TX; The Oncology Institute of Hope and Innovation, Glendale, CA; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA; Oncopeptides AB, Stockholm, Sweden\n\nSafety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).9047 – Session: Lung Cancer—Non-Small Cell Metastatic\n\nJohanna C. Bendell, Patricia LoRusso, Michael J. Overman, Anne M. Noonan, Dong-Wan Kim, John Strickler, Sang-We Kim, Stephen John Clarke, Thomas J. George, Peter S. Grimison, Minal A. Barve, Manik A. Amin, Jayesh Desai, Trisha Wise-Draper, Zachary Cooper, Nairouz Elgeioushi, Nancy Kathryn Mueller, Rakesh Kumar, Kevin YuFeng Wu, Sandip Pravin Patel; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Yale University Cancer Center, New Haven, CT; MD Anderson Cancer Center, Houston, TX; The Ohio State University Wexner Medical Center, Columbus, OH; Seoul National University Hospital, Seoul, South Korea; Duke University Medical Center, Durham, NC; Asan Medical Center, Seoul, South Korea; Royal North Shore Hospital, St. Leonards, Australia; University of Florida/UF Health Cancer Center, Gainesville, FL; Chris O’Brien Lifehouse, Sydney, NSW, Australia; Mary Crowley Cancer Research Center, Dallas, TX; Washington University School of Medicine, St. Louis, MO; Royal Melbourne Hospital, Parkville, VIC, Australia; University of Cincinnati Medical Center, Cincinnati, OH; AstraZeneca, Gaithersburg, MD; Moores Cancer Center, La Jolla, CA\n\nSexual harassment of oncologists.\n\n11001 – Session: Moving Toward Equity\n\nIshwaria Mohan Subbiah, Merry Jennifer Markham, Stephanie L. Graff, Laurie Beth Matt-Amaral, Julia Lee Close, Kent A. Griffith, Reshma Jagsi; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Florida, Gainesville, FL; Sarah Cannon Cancer Institutes HCA Midwest Health, Overland Park, KS; McDowell Cancer Ctr Akron General Medcl Ctr, Medina, OH; University of Florida/UF Health Cancer Center, Gainesville, FL; University of Michigan, Ann Arbor, MI\n\nPredicting response to chemotherapy in neuroblastoma using deep learning: A report from the International Neuro¬¬blastoma Risk Group.\n\n10039 – Session: Pediatric Oncology\n\nSiddhi Ramesh, Diana Michael, Liu Liu, Nicholas Feinberg, Meaghan Granger, Arlene Naranjo, Susan Lerner Cohn, Samuel Louis Volchenboum, Anoop Mayampurath, Mark A. Applebaum; University of Chicago Pritzker School of Medicine (Chicago, IL), Chicago, IL; University of Chicago, Chicago, IL; University of Chicago Department of Medicine, Chicago, IL; University of Chicago Department of Radiology, Chicago, IL; Cook Children’s Medical Center, Fort Worth, TX; Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL; University of Chicago Medical Center, Chicago, IL\n\nRacial and ethnic disparities in risk and survival in children with neuroblastoma: An updated analysis.10036 – Session: Pediatric Oncology\n\nCaileigh Pudela, Mark A. Applebaum, Sang Mee Lee, Arlene Naranjo, Julie R. Park, Samuel Louis Volchenboum, Tara O. Henderson, Susan Lerner Cohn, Ami Vijay Desai; University of Chicago, Chicago, IL; Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL; Seattle Children’s Hospital and University of Washington School of Medicine, Seattle, WA; University of Chicago Medical Center, Chicago, IL; The University of Chicago, Chicago, IL\n\nClinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes in a prospective cohort of 3,995 patients after a median follow-up of 10 years.\n\n10510 – Session: Prevention, Risk Reduction, and Hereditary Cancer\n\nSong Yao, Haiyang Sheng, Marilyn L. Kwan, Qianqian Zhu, Janise M. Roh, Lia D’addario, Isaac J. Ergas, Emily Schultz, Ting-Yuan David Cheng, Warren Davis, Catherine Thomsen, Scarlett Lin Gomez, Christine B. Ambrosone, Lawrence H. Kushi; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Kaiser Permanente Northern California, Division of Research, Oakland, CA; University of Florida, Gainesville, FL; Zero Breast Cancer, Oakland, CA; University of California, San Francisco, San Francisco, CA\n\nFactors associated with endowed chair allocation in medical oncology divisions and departments in the United States.\n\n11044 – Session: Professional Development and Education Advances\n\nLena Jia, Michael Kevin Rooney, Clare Jacobson, Kent A. Griffith, Reshma Jagsi, Merry Jennifer Markham; Washington University School of Medicine, St. Louis, MO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Michigan Medical School, Ann Arbor, MI; University of Michigan, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; University of Florida, Gainesville, FL\n\nNCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.\n\n11506 – Session: Sarcoma\n\nMatthew Ingham, Jacob B. Allred, Katherine Gano, Suzanne George, Steven Attia, Melissa Amber Burgess, Mahesh Seetharam, Sosipatros Alexandros Boikos, Nam Bui, James Lin Chen, Julia Lee Close, Gregory Michael Cote, Premal H. Thaker, S. Percy Ivy, Biswajit Das, Geoffrey Shapiro, Bose Kochupurakkal, Jane B. Trepel, Yves Pommier, Gary K. Schwartz; Columbia University Irving Medical Center, New York, NY; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; Mayo Clinic, Jacksonville, FL; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA; Mayo Clinic Arizona, Scottsdale, AZ; Virginia Commonwealth University Hospital, Richmond, VA; Stanford University, Stanford, CA; The Ohio State University, Columbus, OH; University of Florida/UF Health Cancer Center, Gainesville, FL; Massachusetts General Hospital, Boston, MA; Department of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO; National Cancer Institute, Rockville, MD; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD; Dana-Farber Cancer Institute, Boston, MA; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD"
    }
}